# A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct02792465/  
OnCo record `nct02792465` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CFI-402257 run by University Health Network, Toronto, completed.

## Summary

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT02792465 by University Health Network, Toronto, with 52 participants enrolled, started 2016-11-11. Conditions recorded: Advanced Solid Cancers and Breast Cancer. Interventions recorded: CFI-402257 and Fulvestrant.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02792465
- Phase: 1
- Setting: An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
- Sponsor: University Health Network, Toronto
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT02792465: https://clinicaltrials.gov/study/NCT02792465

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CFI-402257](https://onco.cc/drugs/cfi-402257/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct02792465.json